Peritoneal Serous Carcinoma

About
Mappings

NCI Thesaurus: Primary Peritoneal Serous Adenocarcinoma (coding:ncit:C40023)

OncoTree: Peritoneal Serous Carcinoma (coding:oncotree:PSEC)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib
EMA (1) FDA (4) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (4) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (4) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (4) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (2) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) HRD Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (2) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (2) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (2) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
EMA (1) FDA (2) FOLR1 positive Peritoneal Serous Carcinoma Mirvetuximab soravtansine
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Peritoneal Serous Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Peritoneal Serous Carcinoma Bevacizumab, Paclitaxel, Pembrolizumab